• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY 3 Star

Last Price$49.32Day Change (%)0.41%
Open Price$49.16Day Change ($)0.20
Day Range49.00–49.4952-Week Range41.11–57.49

As of Wed 07/23/2014 03:31 PM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously ...

    Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma

  2. Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program

    Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program

  3. RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology

    RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology

  4. U.S. Hot Stocks: Hot Stocks to Watch

    U.S. Hot Stocks: Hot Stocks to Watch

  5. Research and Markets: PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

    Research and Markets: PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  6. Finding the True Champion Dividend-Growth Funds

    There is more competition among dividend-growth funds, making it harder to truly stand out.

  7. Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program

    Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program

  8. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.